From mitochondrial signals to metabolic receptors.
Metabolic Research Stack
MOTS-c and GLP-3 (retatrutide) offer two distinct ways to explore metabolic-health research: cellular adaptation to stress and multi-receptor endocrine signalling. A concise two-vial selection with clear individual roles.
CURATED INDIVIDUAL ITEMS · TEST / DEMOAT A GLANCE
Inside the stack
MOTS-C
1 × 10 mg single vial · $79.99 CAD each
$79.99 CAD
MOTS-c is a mitochondrial-derived peptide studied for cellular metabolic adaptation. Cell and mouse research explores AMPK-related signalling and how cells respond to metabolic stress.
Metabolic sensing — AMPK-related pathways connect cellular energy status with adaptive responses.
Stress signalling — Experiments investigate stress-responsive movement into the nucleus and changes in gene expression.
Mitochondrial communication — A peptide encoded within mitochondrial DNA offers a distinct perspective on communication within cells.
GLP-3 is the catalogue name for retatrutide, a GIP, GLP-1 and glucagon receptor triple agonist. Controlled clinical research examines metabolic and body-weight endpoints for the investigational molecule.
Three receptor targets — GIP, GLP-1 and glucagon receptor activity frame its metabolic research identity.
Metabolic-health research — Reviewed trials investigate body-weight endpoints in defined populations.
Clinical evidence — Trial interventions and monitored participants are distinct from a catalogue vial or pen.
MOTS-c research examines AMPK-related activity and stress-responsive nuclear signalling in cells and animal models. Retatrutide research examines a GIP/GLP-1/glucagon receptor agonist in controlled metabolic trials. These different study settings help frame the science without predicting a combined outcome.
Explore the evidence & study context
MOTS-C
Cells / animal
The 2015 study linked MOTS-c to AMPK-related cellular signalling and reported altered insulin-resistance outcomes in mouse models.
Cells and mice, not a human efficacy trial or an energy/weight-loss claim for PEPTIVIA material.
Jastreboff et al. (NEJM, 2023) randomized 338 adults with obesity, or overweight plus a weight-related condition, in a 48-week phase 2 trial.
Receptor activity concerns metabolic signalling; measured weight change is a separate endpoint, not proof of an appetite mechanism or a PEPTIVIA product effect.
At week 48, least-squares mean body-weight change was −24.2% in the investigational 12 mg arm (starting at 2 mg), versus −2.1% with placebo; week 24 was the primary endpoint.
This is a specific trial arm and secondary endpoint, not expected weight loss from a purchased vial or a use recommendation.
The stack contains separately labelled vials, not one combined mixture. A constituent such as GLOW or CJC/ipamorelin is itself a premixed blend, as named in the catalogue.
How is the price calculated?
The selected total is the sum of the current retail price of each constituent vial, multiplied by its displayed quantity. Two vials means two single-vial prices, not a bulk tier. No additional stack discount is applied.
Does adding this change a paid order?
No. The items enter your current demo bag together. Existing bag lines increase by their stated quantities; paid test orders remain unchanged. Checkout is simulated.
What handling information is available?
Format, strength and quantity are shown for each item. Storage, identity, purity and handling require verified batch-specific documentation. This collection supplies no dosing or cycle schedule.
Can component evidence prove the collection works?
No. Study findings retain their individual experimental context. A shared research theme does not establish the effects or safety of a combination.
Selank and Semax bring two complementary research questions into view: GABA-related signalling and neurotrophic pathways involved in learning and memory. A focused starting point for exploring stress-response and cognitive neuroscience.
Explore growth-hormone signalling and cellular adaptation with two vials each of CJC-1295 with DAC, ipamorelin and MOTS-c. This collection brings growth-axis and mitochondrial research into one clearly specified selection.